The CAR-T cell therapy market size is expected to grow from US$ 2.79 billion in 2022 to US$ 10.13 billion by 2030.

Factors such as an increase in the burden of cancer globally and innovative product launches propel the CAR-T cell therapy market growth.

Increase in Prevalence of Cancer Globally Drives Market Growth

Air pollution, unhealthy diet, alcohol use, smoking, and physical inactivity are risk factors for noncommunicable diseases like cancer. Certain chronic infections increase the risk of cancer; this is especially problematic in low- and middle-income nations. In 2018, about 13% of cancer cases were diagnosed worldwide. In 2020, cancer was the primary cause of death globally, accounting for almost 10 million deaths. In terms of new cancer cases in 2020, the most prevalent were breast (2.26 million cases), lung (2.21 million cases), colon and rectum (1.93 million cases), prostate (1.41 million cases), skin (non-melanoma 1.20 million cases), and stomach (1.09 million cases).

CAR-T cell therapy is a cutting-edge form of adoptive immunotherapy in which T cells are modified to express synthetic chimeric antigen receptors (CAR). Treatments for hematological malignancies such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, and multiple myeloma have primarily involved the use of CAR-T cells. Solid tumors, such as sarcoma, breast cancer, and melanoma, present significant opportunities for CAR-T cell development and research. T-cell-based techniques are frequently used in cancer immunotherapy due to their higher success rate. In 2021, Labiotech.eu (a leading online media for the biotech industry in Europe) stated that more than 500 CAR T-cells clinical trials for cancer treatment are being carried out globally. Most are being carried out in East Asia, the US, and Europe. Thus, the growing burden of cancer is driving the T-cell therapy market.

Market Trend

Pipeline Advancement in CAR-T Cell Therapy Fields

Ongoing research and development leading to a robust pipeline of next-generation CAR-T therapies with enhanced efficacy and safety profiles will bring new CAR-T cell therapy market trends in the coming years. For instance, ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL)

CAR-T Cell Therapy Market, by Product:

Based on targeted antigen, the CAR-T cell therapy market analysis is carried out by considering the following segments: CD19 and BCMA. The CD19 segment held the largest market share in 2022. CD19, a cell surface protein member of the immunoglobulin superfamily, is also called Cluster of Differentiation 19. It plays a critical role in the human immune system as a marker for B cells. CD19 is primarily expressed on the surface of B cells, but it is also sporadically expressed on other immune cells. It is an important target for research and clinical applications because of its role in B cell development and activation. This, in turn, drives the segment growth.

CAR-T Cell Therapy Market, by Indication:

By indication, the market is segmented as lymphomas, leukemia, and multiple myeloma. The lymphomas segment held the largest CAR-T cell therapy market share in 2022. Treatment for certain types of lymphomas with CAR-T cell therapy has demonstrated encouraging outcomes. The process entails altering a patient's T cells to produce a chimeric antigen receptor that specifically targets particular types of cancer. This novel method has shown to be highly effective, especially in treating B-cell lymphomas that are refractory or have relapsed, such as follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).

Competitive Landscape and Key Companies:

Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., CARsgenTherapeutics Co., Ltd, Aurora Biopharma, Legend Biotech, Pfizer Inc., bluebird bio, Inc., Mustang Bio, Sorrento Therapeutics, Inc., and Fate Therapeutics are the prominent companies in the CAR-T cell therapy market report. These companies focus on new technologies, upgrading existing products, and geographic expansions to meet the growing consumer demand worldwide.